Effect of ceftobiprole on the normal human intestinal microflora

International Journal of Antimicrobial Agents

Volumn 36, Issue 6, 2010, Pages 537-541

  Bäckström, Tobias ^a   Panagiotidis, Georgios ^a   Beck, Olof ^a   Asker Hagelberg, Charlotte ^a   Rashid, Mamun Ur ^a   Weintraub, Andrej ^a   Nord, Carl Erik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Ceftobiprole; Normal human intestinal microflora

Indexed keywords

ANTIBIOTIC AGENT; CEFTOBIPROLE;

ADULT; AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ISOLATION; BACTEROIDES; BIFIDOBACTERIUM; CANDIDA ALBICANS; CHEMICAL ANALYSIS; CLINICAL TRIAL; CLOSTRIDIA; CLOSTRIDIUM DIFFICILE; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CULTURE MEDIUM; DIARRHEA; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG FECES LEVEL; DRUG INDUCED HEADACHE; ENTEROBACTERIACEAE; ENTEROCOCCUS; FEMALE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE EDEMA; INJECTION SITE PAIN; INTESTINE FLORA; LACTOBACILLUS; MALE; MINIMUM INHIBITORY CONCENTRATION; MYALGIA; NAUSEA; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; TASTE DISORDER; THROMBOPHLEBITIS; VAGINA CANDIDIASIS;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIA; CEPHALOSPORINS; COLONY COUNT, MICROBIAL; FECES; FEMALE; FUNGI; GASTROINTESTINAL TRACT; HUMAN EXPERIMENTATION; HUMANS; MALE; METAGENOME; PLASMA;

EID: 78249254876     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.07.021     Document Type: Article

References (13)

1. Sullivan Å., Edlund C., Nord C.E. Interaction between antimicrobial agents and the oropharyngeal and intestinal microflora. Antimicrobial agents 2005, 1357-1370. ASM Press, Washington, DC. A. Bryskier (Ed.).
2. Sullivan Å., Edlund C., Nord C.E. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001, 1:101-114.
3. Barbour A., Schmidt S., Rand K.H., Derendorf H. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2009, 34:1-7.
4. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. London, UK: EMEA; 2000. CPMP/EWP/2655/99.
5. Panagiotidis G., Bäckström T., Asker-Hagelberg C., Jandourek A., Weintraub A., Nord C.E. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother 2010, 54:1811-1814.
6. Nord C.E., Rasmanis G., Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J Antimicrob Chemother 2006, 58:627-631.
7. Manual of clinical microbiology 2007, ASM Press, Washington, DC. 9th ed. P.R. Murray, E.J. Baron, J.H. Jorgensen, M.L. Landry, M.A. Pfaller (Eds.).
8. Huang H., Weintraub A., Fang H., Nord C.E. Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of Clostridium difficile infections. J Clin Microbiol 2009, 47:3729-3731.
9. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M7-A7. Wayne, PA: CLSI; 2006.
10. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard. 7th ed. Document M11-A7. Wayne, PA: CLSI; 2007.
11. Ednie L., Shapiro S., Appelbaum P.C. Antianaerobe activity of ceftobiprole: a new broad-spectrum cephalosporin. Diagn Microbiol Infect Dis 2007, 58:133-136.
12. Schirmer P.L., Deresinski S.G. Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections. Expert Rev Anti Infect Ther 2009, 7:777-791.
13. Murthy B., Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet 2008, 47:21-33.